10x Science Raises $4.8M to Automate Protein Characterization with AI Platform
Key Insights
10x Science (search) secured $4.8 million in seed funding led by Initialized Capital (search) to develop an AI platform that automates protein (search) characterization for drug development.
The platform addresses a critical bottleneck in biologic therapy development by using AI to analyze mass spectrometry data in minutes rather than weeks or months.
Founded by scientists from Nobel Prize-winner Carolyn Bertozzi's lab, the company combines expertise in chemistry, biology, and AI to accelerate drug development timelines.
10x Science (search), an artificial intelligence company focused on molecular-level protein (search) characterization, has raised $4.8 million in seed funding to address a critical bottleneck in drug development. The oversubscribed round was led by Initialized Capital (search), with participation from Y Combinator (search), Civilization Ventures (search), Founder Factor (search), and strategic angel investors.
The funding will support the company's efforts to scale its AI platform that automates protein (search) characterization, a process essential for determining whether biologic therapies (search) are safe, effective, and manufacturable. Despite its importance in developing cancer immunotherapies (search) and gene therapies (search), this work remains largely manual, requiring specialized scientists to spend weeks or months interpreting complex mass spectrometry data using legacy tools.
Automating Complex Molecular Analysis
10x Science (search)'s platform applies AI models to analyze hundreds of thousands of spectra, identify molecular structures and chemical modifications, and deliver explainable insights in minutes. This capability is designed to significantly accelerate drug development timelines while improving accuracy and scalability.
"The people building AI have historically not been life scientists, and the life scientists have not been building AI; we come from both worlds," said David Stephen Roberts, Co-Founder and CEO of 10x Science (search). "We realized we could build something that had never existed: an AI system with the scientific depth to reason about proteins the way the best experts do, but at a speed and scale no human team can match."
The platform introduces a "deep memory" capability that allows it to learn from each dataset over time, building a continuously evolving understanding of molecular profiles across different organizations. Unlike traditional tools that reset with each analysis, 10x Science (search)'s system accumulates knowledge, enabling more accurate and context-aware insights.
Addressing Industry Pain Points
The company was founded by David Stephen Roberts, Andrew Reiter, and Vishnu Tejus, who met while working in the Nobel Prize-winning laboratory of Carolyn Bertozzi. The founding team combines expertise in chemistry, biology, and artificial intelligence, with backgrounds spanning academia and entrepreneurship.
"AI has already made meaningful contributions to biology at the prediction layer, asking what a protein (search) might look like based on its sequence," explained Andrew Reiter, Co-Founder and COO. "What no one has built is AI for the characterization layer, where you interpret real experimental data from real therapeutic molecules: that is the layer where drug development decisions are actually made, and it has remained painfully manual."
The technology addresses what investors are calling the "validation gap" in AI-driven biotech. While AI models excel at pattern recognition and molecular design, they struggle to predict real-world performance across the complex cascade of biological interactions that determine drug candidate success or failure.
Market Opportunity and Applications
10x Science (search) is positioning its technology as a foundational layer for the pharmaceutical industry, where demand for protein (search) characterization is rapidly increasing due to the growing complexity of biologic therapies (search). The platform has applications across multiple domains, including cancer (search) research, neurodegenerative diseases (search), infectious diseases (search), and agricultural biotechnology.
"Biologics are the fastest-growing segment of the pharmaceutical industry and are the most complex to develop," noted a company spokesperson. "Every antibody, every cell therapy (search), every engineered protein (search) requires characterization at a level of detail that existing tools simply weren't designed to handle. The field has outgrown its infrastructure."
The industry wastes an estimated $2 billion annually on drug candidates that fail in early clinical trials due to problems that better preclinical analysis could have identified. For pharmaceutical companies, the value proposition is straightforward: reduce costly failures by improving molecular selection upfront.
Strategic Vision and Next Steps
With the new funding, 10x Science (search) plans to expand its engineering team, deepen collaborations with pharmaceutical and biotech partners, and continue developing its AI models to support a broader range of molecular analysis use cases.
"This is a critical moment in pharma; the industry is looking for AI that actually works, and protein (search) characterization is needed at every stage of the drug lifecycle regardless of whether any single drug succeeds or fails," said Zoe Perret, Partner at Initialized Capital (search). "We're talking about the infrastructure layer of drug development."
The company's long-term vision is to create a shared layer of molecular intelligence that aggregates insights across the life sciences, enabling researchers and organizations to better understand the biological mechanisms underlying health and disease. As Roberts noted, this approach could finally enable the pharmaceutical industry to answer a fundamental question: "across thousands of characterized therapeutics, what molecular patterns distinguish the drugs that work from the ones that do not."